Antibiotic may slow Lou Gehrig’s disease

Dr. Jeffery Rosenfeld, chief of neurology at the UCSF medical education program, is enrolling ALS patients in a national trial to examine the potential therapeutic effects of ceftriaxone, an intravenous antibiotic currently approved by the FDA to treat bacterial infections. Dr. Rosenfeld says that ceftriaxone appears to protect motor neurons from damage, and that the drug could slow degeneration. Phase 1 and 2 studies that were begun in 2006 showed that the drug was safe, and this Phase 3 study will test for efficacy.

Click here to read more.

Share this: